... II trials combining ifosfamide, carboplatin and etoposide chemotherapy (ICE) showed favorable results. We therefore applied the ICE protocol to 13 patients (10 GBM, 3 anaplastic astrocytomas). Partial or complete remissions were not observed. None of the 13 patients survived progression-free for 6...

... was evaluated to improve the efficacy of thermoradiotherapy in poor-prognosis lesions (i.e. ≥1 cm 2 or ≥ 14 cm 3 ) which have an expected CR rate of ∼ 30 ± 8%. Patients were entered into a two-arm phase-II study: arm 1 = breast cancer (10 patients), ifosfamide (1.5 g/m 2 ) + epirubicin (20 mg/m 2 ) + HT + RT...

... towards a higher prevalence of subclinical tubular changes was observed in patients with higher cumulative doses of methotrexate or ifosfamide and in patients with combined Ctx and Rtx with radiation fields involving the renal area. Changes in glomerular function were not observed. It is concluded...

..., in a prior study, it has been shown to be active in tumors that have displayed resistance to platinum compounds, with a reported response rate of 20%. Ifosfamide has shown activity in the treatment of patients who previously demonstrated clinical resistance to a platinum-cyclophosphamide combination...

...Vasant R. Pai; Deepak M. Parikh; Alka T. Mazumdar; Raja S. Rao 152 patients with histologically proven squamous cell carcinoma of the head and neck (advanced and/or recurrent) were treated with a single drug therapy of ifosfamide 1.5 g/m 2 by intravenous drip for half an hour in 125 ml of dextrose...

...Reinhard Becher; Herbert Höfeler; Otto Kloke; Dieter May; Ursula Wandl; Norbert Niederle; Rudolf Richter; Max E. Scheulen; Carl G. Schmidt A total of 51 fully evaluable patients with advanced and intensively pretreated breast cancer were treated with a combination chemotherapy of ifosfamide plus...

...Mert Basaran; E. Sevil Bavbek; Sezer Saglam; Levent Eralp; Burak Sakar; Ata Can Atalar; Bilge Bilgic; Harzem Ozger; Haluk Onat Background: Osteosarcoma is a rare malignancy, and patients with this disease benefit from adjuvant chemotherapy. While cisplatin, anthracyclines and ifosfamide...

...Christos Kosmas; Nicolas Tsavaris; Aggelos Koutras; Thomas Makatsoris; Nicolas Mylonakis; George Tzelepis; Antonis Dimitrakopoulos; Konstantinos Spyropoulos; Aristidis Polyzos; Athanasios Karabelis; Haralambos P. Kalofonos Purpose: In the present phase II study we evaluated the docetaxel-ifosfamide...

...F. Boccardo; P. Guglielmini The therapeutic activity of ifosfamide in urologic tumors has been reviewed. Ifosfamide has definite activity in nephroblastoma, where it represents the treatment of choice for children who are not cured by front-line chemotherapy, and for the adults who are diagnosed...

...C. Boni; F. Zanelli In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20–25...

...J. Klastersky Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis. Mesna administration can control the urothelial toxicity of ifosfamide...

..., the majority of patients with HR-STS recruited for this multimodality treatment protocol cannot be controlled by standard procedures. All eligible patients will be randomized to receive either 4 cycles of EIA (etoposide 250 mg/m 2 + ifosfamide 6 g/m 2 + doxorubicin 50 mg/m 2 ) within 12 weeks (chemotherapy...

...R. Sorio; D. Lombardi; S. Spazzapan; N. La Mura; G. Tabaro; A. Veronesi Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has increased its safety, avoiding the main dose-limiting side effect...

...A.A. Lissoni; F. Fei; R. Rossi; R. Fruscio; A. Villa; G. Zani Ifosfamide is one of the best-known alkylating agents. In advanced epithelial ovarian cancer, it has been tested in association with cisplatin, achieving results equal, if not better than cyclophosphamide, with acceptable toxicity...

...A. Buda; T. Dell’Anna; M. Signorelli; C. Mangioni Ifosfamide, a cyclophosphamide analogue, has demonstrated a wide spectrum of activity against numerous neoplasms in different oncologic areas, including paediatric, haematological, breast, lung and testicular cancers, soft tissue sarcomas...

...L.H. Einhorn Ifosfamide has always had significant single-agent activity in patients with germ cell tumors. We first began studies of cisplatin + ifosfamide combination chemotherapy as salvage chemotherapy in 1982. The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially...

...M. Marangolo; P. Giovanis Recent literature about the treatment options of small cell lung cancer stresses the role of ifosfamide both alone and in combination with either cisplatin or carboplatin and etoposide. Its pharmacokinetics and the lower hematological toxicity permit the use of high doses...

...G. Binotto; L. Trentin; G. Semenzato Ifosfamide (IF) and cyclophosphamide (CTX) are chemotherapeutic agents frequently used in the treatment of human malignancies. These drugs can exhibit a bimodal mechanism of antitumor action with cytotoxic and immunomodulatory effects when associated...

...M. Furlanut; L. Franceschi Ifosfamide is a bifunctional alkylating agent, used as a racemic mixture by intravenous route in the treatment of various tumors. It is an oxazaphosphorine derivative with a structural formula similar to that of cyclophosphamide. As a prodrug it requires activation...

...P. Nicolao; B. Giometto Ifosfamide is an alkylating agent with well-demonstrated efficacy against a large number of malignant diseases. With cyclophosphamide it shares a toxicity profile characterized by myelosuppression and urotoxicity, but ifosfamide has additionally disclosed adverse...